Arizona State University

Peter Jurutka

Carl Wagner

Pamela A Marshall

Arjan Van Der Vaart

Todd Sandrin

The invention provides compounds formula (I) and salts thereof: wherein R-Rhave any of the values defined in the specification. The compounds are useful for treating conditions including Alzheimer's disease, Parkinson's disease, diabetes, cancer, inflammation, hyperresponsiveness, allergic conditions, asthma, and psychotic disorders such as schizophrenia. The compounds are also useful to lower IL-4, IL-5, or IL-15 levels in an animal.

Substituted anilines for treatment of animal diseases

The invention provides compounds of formulae I, II, III, and IV: and salts thereof, as well as pharmaceutical compositions comprising such compounds. The compounds are useful for treating cancers and Alzheimer's disease.

Therapeutic compounds

The invention provides a method for a disease or condition associated with dopamine deficiency (e.g. depression, schizophrenia, or Parkinson's disease) in a mammal in need of such treatment comprising administering a compound that binds to RXR to the mammal.

Therapeutic methods

The invention provides compounds of formula I: and salts thereof, as well as pharmaceutical compositions comprising such compounds. The compounds are useful for treating cancers, Alzheimer's disease, and conditions associated with demyelination.

Dihydroindene and tetrahydronaphthalene compounds

Isochroman compounds and methods of use thereof

We have identified a suite of genes in a limited number of human colonic tissue samples with expression patterns that correlate with whether an individual is experiencing symptoms of Irritable Bowel Syndrome (IBS) (FIG.). Interestingly, in the efforts to screen for genes that might be used as biomarkers for IBS, it was found that no single gene could be used for this purpose. Instead, when examining the entire dataset, there exist signature gene expression patterns (e.g., fingerprints or biosignatures) of IBS that have use as a diagnostic tool for IBS.

Gene expression based biomarker system for irritable bowel syndrome (IBS) diagnosis

The invention provides alkyl benzene compounds. The compounds are useful for treating conditions including Alzheimer's disease, Parkinson's disease, diabetes, cancer, inflammation, hyperresponsiveness, allergic conditions, asthma, and psychotic disorders such as schizophrenia. The compounds are also useful to lower IL-4, IL-5, or IL-15 levels in an animal.

The invention provides compounds formula (I) and salts thereof: wherein the bond represented by ---- is a single bond or a double bond, and R1 has any of the values defined in the specification. The compounds are useful for treating conditions including Alzheimer's disease, Parkinson's disease, diabetes, cancer, and psychotic disorders such as schizophrenia. 

The invention provides compounds and compositions that are useful for treating conditions including Alzheimer's disease, Parkinson's disease, diabetes, cancer, and psychotic disorders such as schizophrenia.

The invention provides compounds of formulae (I), (II), (III), and (IV): and salts thereof, as well as pharmaceutical compositions comprising such compounds. The compounds are useful for treating cancers and Alzheimer's disease. 

The present invention relates to analogs of bexarotene and methods of use thereof.

Growing community of inventors

Scottsdale, AZ, United States of America

Peter Jurutka